Strategic thinking, operational excellence
Your trials need speed, precision, and quality—we know it. Our dedication to respiratory and infectious diseases means we provide in-depth scientific insights and tailor our processes and teams to meet the demands of your project. Throughout the process we act as your partner, in full integration with your team. Our senior management will guide strategic thinking and remain involved through every aspect of your trial.
When you launch into a complex and fast-paced respiratory or infectious disease trial, choose a CRO that understands the unique demands of these categories. Our medical and scientific specialists and operational staff have managed all phases of clinical trials in respiratory and infectious disease medicine, including design, execution, analysis, and interpretation. We understand, anticipate, adapt, and deliver, while staying attuned to the therapeutic nuances of each indication—and your goals.
Respiratory specialty
i3 RID has the expertise to handle respiratory trials and their challenges, which include narrow time windows and seasonal and regional factors. Our experience encompasses a broad spectrum of indications of respiratory clinical trials, and we have developed a network of prominent investigators ready to work on your projects.
i3 RID was instrumental in managing a large international Phase III pediatric vaccine trial that included 170 sites and 36,000 subjects.
Infectious disease expertise
Whether it’s finding the right patient populations anywhere on the globe or understanding sponsor and site challenges in a rapidly evolving regulatory and therapeutic environment, i3 has experience managing the complexities of infectious disease trials.
Expanded access, patient registries
In addition to managing Phase I–III programs, we also have experience with late phase trials, including expanded access and patient registry studies. Our detailed understanding of these programs enables us to plan, launch, and run them with great efficiency and flexibility.
Why i3?
As therapeutic specialists, our experience is broad and international. Since January 2002, i3 has completed or is currently managing more than 75 respiratory or infectious disease studies at over 8,600 sites in more than 81,000 patients with various sponsors. Through this experience we have built a network of contacts with physicians and institutions invested in respiratory and infectious diseases trials worldwide. |
